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Background: Stratification of patients according to their clinical prognosis is a desirable goal in cancer treatment in
order to achieve a better personalized medicine. Reliable predictions on the basis of gene signatures could support
medical doctors on selecting the right therapeutic strategy. However, during the last years the low reproducibility of
many published gene signatures has been criticized. It has been suggested that incorporation of network or
pathway information into prognostic biomarker discovery could improve prediction performance. In the meanwhile
a large number of different approaches have been suggested for the same purpose.
Methods: We found that on average incorporation of pathway information or protein interaction data did not
significantly enhance prediction performance, but indeed greatly interpretability of gene signatures. Some methods
(specifically network-based SVMs) could greatly enhance gene selection stability, but revealed only a comparably
low prediction accuracy, whereas Reweighted Recursive Feature Elimination (RRFE) and average pathway expression
led to very clearly interpretable signatures. In addition, average pathway expression, together with elastic net SVMs,
showed the highest prediction performance here.
Results: The results indicated that no single algorithm to perform best with respect to all three categories in our
study. Incorporating network of prior knowledge into gene selection methods in general did not significantly
improve classification accuracy, but greatly interpretability of gene signatures compared to classical algorithms.Background
Molecular biomarkers play an important role in clinical
genomics. Identification and validation of molecular
biomarkers for cancer diagnosis, prognosis, and subsequent
treatment decision becomes an important problem in per-
sonalized medicine. Modern technologies, like DNA micro-
arrays and deep sequencing methods, can measure
thousands of gene expression profiles at same time, which
can be used to indentify patterns of gene activity that might
provide criteria for individual risk assessment in cancer
patients.* Correspondence: frohlich@bit.uni-bonn.de
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distribution, and reproduction in any mediumBiomarker discovery poses a great challenge in
bioinformatics due to the very high dimensionality of
the data coupled with a typically small sample size. In
the past a large number of classification algorithms
have been developed or adopted from the machine
learning field, like PAM, SVM-RFE, SAM, Lasso and
Random Forests [1-4]. Several adaptations of Support
Vector Machines (SVM) [5] have been suggested for
gene selection in genomic data, like L1-SVMs, SCAD-
SVMs and elastic net SVMs [6-8]. Although these
methods show reasonably good prediction accuracy,
they are often criticized for their lack of gene selec-
tion stability and the difficulty to interpret obtained
signatures in a biological way [9,10]. These challengesntral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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gene selection methods.
To overcome the disadvantages of conventional appro-
aches Chuang et al. [11] proposed an algorithm that incor-
porates of protein-protein interaction information into
prognostic biomarker discovery. Since then a number of
methods going into the same direction have been published
[11-17].
In this article, we compared fourteen published gene se-
lection methods (eight using network knowledge) on six
public breast cancer datasets with respect to prediction ac-
curacy, biomarker signature stability and biological inter-
pretability in terms of an enrichment of disease related
genes, KEGG pathways and known drug targets. We found
that incorporation of network information could generally
not improve prediction accuracy significantly, but could
sometimes indeed improve gene selection stability and bio-
logical interpretability of biomarker signatures drastically.
Specifically, Reweight Recursive Feature Elimination
(RRFE) [17] and average pathway expression led to a very
clear interpretation in terms of enriched disease relevant
genes, pathways and drug targets. On the other hand, net-




We employed fourteen published gene selection methods
in this article. In machine learning features selection
methods can be classified into three categories [18]: filters,
wrappers and embedded methods. Filter methods select a
subset of features prior to classifier training according to
some measure of relevance for class membership, e.g.
mutual information [19]. Wrapper methods systematically
assess the prediction performance of feature subsets, e.g.
recursive feature elimination (RFE) [3]; and embedded
methods perform features selection within the process of
classifier training. The methods we employed in this
article covered all three categories. Furthermore we can
classify feature selection methods according to whether or
not they incorporate biological network knowledge (con-
ventional vs. network-based approaches).
As one of the most basic approaches, we considered
here a combination of significance analysis of microar-
rays (SAM) [20] as a filter prior to SVM or Naïve Bayes
classifier learning. More specifically, only genes with
FDR < 5% (Benjamini-Hochberg method) [21] were con-
sidered as differentially expressed. As further classical
gene selection methods we considered prediction ana-
lysis for microarrays (PAM) [2], which is an embedded
method, and recursive feature elimination (SVM-RFE)
[3], an SVM-based wrapper algorithm. Moreover, we
included SCAD-SVMs [7] and elastic-net penalty SVMs
(HHSVM) [8] as more recently proposed embeddedapproaches that particularly take into account correla-
tions in gene expression data. In this article we used
SAM+SVM (significant gene SVM), SAM+NB (signifi-
cant gene Naïve Bayes classifier), PAM, SCAD-SVM,
HHSVM and SVM-RFE as conventional feature selection
methods that do not employ network knowledge.
The following network-based approaches for inte-
grating network or pathway knowledge into gene se-
lection algorithms were investigated: Mean expression
profile of member genes within KEGG pathways
(aveExpPath) [22], graph diffusion kernels for SVMs
(graphK; diffusion kernel parameter δ=1) [12], p-step
random walk kernels for SVMs (graphKp; parameters
p=3, α=2, as suggested by Gao et al.) [23], pathway
activity classification (PAC) [13], gradient boosting
(PathBoost) [14] and network-based SVMs (parameter
sd. cutoff=0.8 for pre-filtering of probesets according
to their standard deviation) [15]. In case of
avgExpPath whole KEGG-pathways were selected or
not selected based on their average differential expres-
sion between patient groups. This was done based on
a SAM-test with FDR cutoff 5% (see above). In case
of diffusion and p-step random walk kernels the
SVM-RFE algorithm was adopted for gene selection
using the implementation in the R-package pathClass
[24]. Furthermore, pathClass was used to calculate the
diffusion kernel. This implementation is directly based
on [12] and only keeps the 20% smallest eigenvalues
and corresponding eigenvectors of the normalized
graph Laplacian to compute the kernel matrix.
PAC and PathBoost come with an own mechanism to
select relevant genes. PathBoost incorporates network
knowledge directly into the gradient boosting procedure
to perform gene selection, whereas PAC first selects genes
within each KEGG-pathway based on a t-test and then
summarizes gene expression in each pathway to a pathway
activity score. According to the original paper by Lee et al.
[13] only the top 10% pathways with highest differences in
their activity between sample groups were selected.
Recently, Taylor et al. [16] found that differentially
expressed hub proteins in a protein-protein interaction
network could be related to breast cancer disease out-
come. We here applied their approach (called HubClassify)
as follows: the random permutation test proposed in Taylor
et al. [16] was used to select differentially expressed hub
genes with FDR cutoff 5%. Hubs were here defined to be
those genes, whose node degree fell into the top 5% per-
centile of the degree distribution of our protein interaction
network. Afterwards a SVM was trained using only those
differential hub genes. Finally, we considered the recently
proposed Reweighted Recursive Feature Elimination
(RRFE) algorithm [17], which combines GeneRank [25]
and SVM-RFE as implemented in the pathClass package
[24]. In summary average pathway expression (aveExpPath),
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walk graph kernels for SVMs (graphKp), PAC, PathBoost,
networkSVM and HubClassify are considered in our
comparison of network-based gene selection methods.
For all SVM classifiers used in this study the soft-margin
parameter C was tuned in the range 10-3, 10-3, 10-2, ..., 103
on the training data. For that purpose the pathClass pack-
age was employed, which uses the span-bound for SVMs
as a computationally attractive and probably accurate al-
ternative to cross-validation [26]. For elastic net SVMs and
SCAD-SVMs we used the R-package penalizedSVM [27],
which allows for tuning of hyperparameters (elastic net:
λ12[2-8,214], λ2 set in a fixed ratio to λ1 according to [8];
SCAD-SVM: λ2[2-8,214]) based on the generalized ap-
proximate cross-validation (GACV) error as another com-
putationally attractive alternative to cross-validation. The
EPSGO algorithm described in [28] was used for finding
optimal hyper-parameter values within the defined ranges.
Note that in any case only the training data were used for
hyper-parameter tuning.
It should be mentioned that for conventional approaches
all probesets on the chip were considered. This is in agree-
ment with a typical purely data driven approach with no
extra side information. Please note that an a-priori restric-
tion to probesets, which can be mapped to a pre-defined
network, would already include a certain level of extra
background knowledge with corresponding assumptions.
Classification performance and stability of a signature
In order to assess the prediction performance for our tested
gene selection methods, we performed a 10 times repeated
10-fold cross-validation. That means the whole data was
randomly split into 10 folds, and each fold sequentially left
out once for testing, while the rest of the data was used for
training and optimizing the classifier (including gene selec-
tion via filtering methods, standardization of expression
values for each gene to mean 0 and standard deviation 1,
etc.). The whole process was repeated 10 times. It should be
noted extra that also standardization of gene expression
data was only done on each training set separately and the
corresponding scaling parameters then applied to the test
data.
The area under receiver operator characteristic curve
(AUC) [29] was used here to measure the prediction
accuracy, and the AUC was calculated by R-package ROCR
[30]. To assess the stability of features selection methods,
we computed the selection frequency of each gene within
the 10 times repeated 10-fold cross-validation procedure.
That means a particular gene could be selected at most 100
times.
Functional analysis of signature genes
To interpret a signature gene in terms of biological
function, we performed an enrichment analysis in terms ofcancer-related disease genes, KEGG pathways and known
drug targets for the prognosis biomarkers via Fishers exact
test. We employed FunDO [31] to look for enrichment of
disease related genes. FunDO uses a hyper-geometric test to
find relevant diseases. Multiple testing correction was done
using Bonferronis method [32]. Furthermore, an analysis of
enriched KEGG pathways based on a hypergeometric test
was done (multiple testing correction via Benjamini-Yeku-
tieli’s method [33]). We also carried out an enrichment ana-
lysis for known targets of therapeutic compounds against
breast cancer. For that purpose, we retrieved a list of 104
proteins and respective therapeutic compounds in breast
cancer, which are either in clinical trials (also withdrawn
ones), FDA approved or on the market with the help of
the software MetaCore™ (see Additional file1: Table S1).
Fisher’s exact test was then used to assess statistical over-
representation of drug targets within each signature.
Datasets
Microarray gene expression data
We collected six public breast cancer Affymetrix HGU133A
microarray (22,283 probesets) datasets [34-39], which are
further described in Table 1. The six datasets were obtained
via Gene Expression Omnibus [40], and normalization was
carried out using FARMS [41]. As clinical end points we
considered metastasis free (datasets by Schmidt et al.,
Ivshina et al.) and relapse free (other datasets) survival time
after initial clinical treatment, depending on the availability
of the corresponding information in the original data. Time
information was dichotomized into two classes according
whether or not patients suffered from a reported relapse/
metastasis event within 5 years. Patients with a survival time
shorter than 5 years without any reported event were not
considered and removed from our datasets.
Protein-protein interaction (PPI) network
A protein interaction network was compiled from a
merger of all non-metabolic KEGG pathways [42]- only
gene-gene interactions were considered – together with
the Pathway Commons database [43], which was own-
loaded in tab-delimited format (May 2010). The purpose
was to obtain an as much as possible comprehensive net-
work of known protein interactions.
For the Pathway Commons database the SIF interactions
INTERACTS_WITH and STATE_CHANGE were taken
into accounta] and any self loops removed. For retrieval
and merger of KEGG pathways, we employed the R-
package KEGGgraph [44]. In the resulting undirected net-
work graph we had 13,840 nodes and 397,454 edges.
Nodes in this network were identified via Entrez gene IDs.
The R package, hgu133a.db [45], was employed to
map probe sets on the microarray to nodes in the
PPI-network. This resulted in a protein-protein inter-
action network matrix of dimension 8886×8886,
Table 1 Employed breast cancer data sets
GEOid Patients dmfs/rfs with event< 5 years dmfs/rfs _ 5 years source
GSE2034 286 93 183 Wang et al. 2005 [34]
GSE1456 159 34 119 Pawitan et al. 2005 [35]
GSE2990 187 42 116 Sotiriou et al. 2006 [36]
GSE4922 249 69 159 Ivshina et al. 2006 [37]
GSE7390 198 56 135 Desmedt et al. 2007 [38]
GSE11121 200 28 154 Schmidt et al. 2008 [39]
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tein in the PPI-network. Accordingly, expression
values for probesets on the microarray that mapped
to the same gene in the network were averaged. Pro-
besets, which could not be mapped to the PPI net-
work, were ignored for all network based approaches
except for RRFE, which according to Johannes et al.
[17], assigns a minimal gene rank to them.
Results and discussion
Predictive power and stability
We assessed the prediction performance of prognos-
tic biomarker gene signatures obtained by fourteen
gene selection methods on six gene expression data-
sets in terms of area under ROC curve (AUC)
(Figure 1). The gene selection stability of each gene
selection method is depicted in Figure 2 (fraction of
constantly selected probe sets) and Additional file 2:
Figure S1 in the Supplements (fraction of probe set
that were selected 10, 20, . . ., 100 times during the
10 x 10-fold CV procedure).
In general, we observed a large variability of prediction
performances of individual methods between different data-
sets. This is not necessarily surprising, since it is known
that the performance of any machine learning algorithms
is dependent on the data at hand. Moreover, each dataset
under study here contains different patients with unique
characteristics and also clinical end points were slightly
different (relapse free versus metastasis free survival after
treatment). We are convinced that a comparison on a
larger number of datasets reveals more of the true
variability of an algorithm than a typical comparison
on few selected ones.
We combined median AUC values for all methods
across datasets into a summary plot (Additional file 3:
Figure S2) and assessed the statistical significance be-
tween methods via a 2-way ANOVA analysis with
Tukey’s post-hoc test. Briefly, the ANOVA analysis
modelled AUC values by a method and a dataset fac-
tor as well as an interaction term between them. This
generally revealed only small effect sizes (average
differences between methods), of which, nonetheless,
a couple could be identified as statistically significant(Additional file 4: Table S2, Additional file 5: Table
S3, Bonferroni adjusted p-value cutoff 5%). Overall
PAC, graph diffusion kernels, p-step random walk
kernels, RFE and significant gene SVMs were almost
consistently outperformed by the other methods. On
the other hand, HHSVM and average pathway expres-
sion were identified as best performing methods
(Table 2). A general advantage for network based
approaches could not be identified among our tested
methods. However, some network-based methods
(specifically network-based SVM, hub-based classifica-
tion, pathBoost) revealed significantly higher gene se-
lection stability (Figures 2, Additional file 2: Figure
S1). Network-based SVMs performed clearly outstanding
here. The reason might be two-fold: On one hand
network-based SVMs come with a pre-filtering step of
probesets according to their standard deviation, which
already drastically reduces the set of considered pro-
besets for the later learning phase and thus naturally
enhances stability. On the other hand network-based
SVMs have a very effective mechanism for grouped
selection of network connected genes via the infinity
norm penalty [15]. Nonetheless, we found network-
based SVMs to show a comparably poor prediction
performance. This underlines that an improved gene
selection stability does not necessarily coincide with
better prediction performance. The reason for this be-
haviour could be that many genes reveal a high correlation
in their expression. If such highly correlated genes are itself
correlated with the patient group, then picking any of these
genes leads to a similar prediction performance. On the
other hand, picking preferentially one particular gene out
of the correlated group (as tried by network-based
approaches) increases gene selection stability, but does not
necessarily increase prediction performance, either. This is
exactly the behaviour we can observe in our datasets:
Some network-based approaches (specifically net-
workSVM) have significantly improved gene selection sta-
bility, but do not perform consistently better than
conventional methods, like PAM. We would like to point
out that the high stability of network based SVMs and hub
based classification is not at all associated to a higher
number of selected genes (Additional file 6: Figure S3).
Figure 1 Prediction performance in terms of area under ROC curve (AUC) PAM (prediction analysis of microarray data), sigGenNB
(SAM+Naïve Bayes), sigGenSVM (SAM+ SVM),SCADSVM, HHSVM (Huberized Hinge loss SVM), RFE (Recursive Feature Elimination), RRFE (Reweighted
Recursive Feature Elimination), graphK (graph diffusion kernels for SVMs), graphKp (p-step random walk graph kernel for SVMs), networkSVM
(Network-based SVM), PAC (Pathway Activity Classification), aveExpPath (average pathway expression), HubClassify (classification by significant hub
genes), pathBoost.
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Figure 2 Signature stability. The y-axis shows the fraction of genes, being selected between 91 and 100 times.
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Table 2 ANOVA analysis for prediction performance (AUC)















network based (average) 3.625
classical (average) 4.17
PAM (prediction analysis of microarray data), sigGenNB (SAM+Naïve Bayes),
sigGenSVM (SAM+ SVM),SCAD-SVM, HHSVM (Huberized Hinge loss SVM), RFE
(Recursive Feature Elimination), RRFE (Reweighted Recursive Feature
Elimination), graphK (graph diffusion kernels for SVMs), graphKp (p-step
random walk graph kernel for SVMs), networkSVM (Network-based SVM), PAC
(Pathway Activity Classification), aveExpPath (average pathway expression),
HubClassify (classification by significant hub genes), pathBoost.
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depth. For that purpose we introduced a gene selection sta-
bility index (SI) for each algorithm across datasets: For each
algorithm we recorded the fraction of genes being selected
1–10, 11–20, 21–30, 31–40, 41–50, 51–60, 61–70, 71–80,
81–90, 91–100 times on dataset i. These fractions (basically
making up a histogram) are summarized into a vector fi.
The theoretically optimal gene selection behavior would be
the vector e = (0,0,0,0,0,0,0,0,0,1)T, which means that all
genes are selected consistently. Based on that we computed






jjf i−e jj22 ð1Þ
Here n is the number of datasets. A ranking of all
algorithms according to this stability index is shown
in Table 3. This highlighted the much different behav-
ior of networkSVM compared to all other approaches,
which, given our previously discussed findings, was
not very surprising. As second best method with re-
spect to gene selection stability we identified hub-
based classification. The high stability of this approach
can be explained by the a-priori restriction on hub
genes.We also investigated gene selection from a different
perspective. We ran a SAM analysis on each of our
datasets and plotted the fraction of top the 100 genes
(sorted by FDR) that were selected by each investi-
gated algorithm (Additional file 7: Figure S4). This
analysis thus focused on the ability of algorithms to
select differentially expressed genes. Not very surpris-
ingly, in this comparison significant gene SVM and
NB revealed the top performance, followed by average
pathway expression. This shows that selected path-
ways typically contained many genes with high fold
change, which altered the overall average pathway ac-
tivity together.Biological interpretability
To investigate the biological interpretability of our found
signatures, we performed an enrichment analysis with re-
spect to KEGG pathways, Disease Ontology terms and
known drug targets. For that purpose we trained each of
the above described methods once on the whole dataset to
retrieve a final gene signature.
In generally, this analysis revealed a high enrichment of
disease related genes, KEGG pathways and known drug
targets in signatures selected by network-based approaches
(Figures 3, 4, 5). Specifically, RRFE (and partially also
aveExpPath with regard to pathways) yielded an extremely
high enrichment with respect to all three categories on all
datasets. The overrepresentation of known drug targets for
genes selected by RRFE was absolutely outstanding on all
datasets. Consistently enriched KEGG-pathways for gene
signatures selected by RRFE and aveExpPath were Path-
ways in cancer, MAPK signaling pathway, ErbB signaling
pathway, Adherens junction and Focal adhesion, which
have all been related to breast cancer [46-49].
The reason for the good interpretability of pathways
selected by AvgExpPath is directly clear, since this
method focuses on selection of whole pathways. The
outstanding interpretability of genes selected by RRFE
can be explained as follows: RRFE uses a modification of
Google’s PageRank algorithm (GeneRank – [25]) to com-
pute for each gene a rank according to its own fold
change and its connectivity with many other differen-
tially expressed ones (guilt by association principle). This
rank is then used to re-scale the hyperplane normal
vector of a SVM. This method automatically leads to a
preference of genes which are central in the network
(c.f. [17]). These central genes are often well studied
and directly known to be disease related [50].Conclusion
In this paper we performed a comprehensive and
detailed comparison of fourteen gene selection meth-
ods (eight integrating network information) in terms
Table 3 Gene selection stability according to stability index (lower =better)
gene selection method GSE2034 GSE11121 GSE1456 GSE2990 GSE4922 GSE7390 Median
PAM 0.237 0.282 0.259 0.302 0.281 0.277 0.279
sigGenNB 0.209 0.193 0.173 0.289 0.208 0.272 0.208
sigGenSVM 0.209 0.193 0.173 0.289 0.208 0.272 0.208
SCAD 0.245 0.265 0.268 0.232 0.229 0.251 0.247
HHSVM 0.212 0.191 0.210 0.199 0.197 0.205 0.202
RFE 0.285 0.298 0.295 0.287 0.293 0.291 0.292
RRFE 0.224 0.240 0.211 0.246 0.209 0.248 0.232
graphK 0.276 0.290 0.295 0.285 0.283 0.285 0.285
graphkKp 0.269 0.281 0.276 0.271 0.273 0.276 0.274
networkSVM 0.021 0.027 0.018 0.026 0.014 0.018 0.020
PAC 0.249 0.257 0.245 0.259 0.158 0.181 0.248
aveExpPath 0.189 0.192 0.156 0.294 0.190 0.237 0.191
HubClassify 0.215 0.095 0.073 0.106 0.138 0.120 0.113
pathBoost 0.200 0.206 0.247 0.199 0.235 0.213 0.210
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interpretability on six public breast cancer datasets.
In general we could not identify one single algo-
rithm to perform best with respect to all three cat-
egories. Much more, we found that incorporating
network of pathway knowledge into gene selection
methods in general did not significantly improve clas-
sification accuracy compared to classical algorithms.
Network-based SVMs drastically enhanced gene selec-
tion stability, but showed a comparably poor predic-
tion performance. On the other hand RRFE lead to
highly interpretable gene signatures with moderate
prediction accuracy, but certainly not extremely high
stability (although significantly better than RFE). Rela-
tively simple gene selection methods, like average
pathway expression, revealed a good prediction accur-
acy. Similar results have been reported in Haury et al.
[51]. Nonetheless, it is worth mentioning that the cru-
cial assumption made by average pathway expression,
namely that the mean pathway activity is altered sig-
nificantly between two patient groups, might not al-
ways be fulfilled, for instance, if only few genes in a
pathway are differentially expressed. Thus this method
should be applied with care.
We found HHSVM and SCAD-SVM in most cases
to show a better prediction performance than SVM-
RFE. This is, for instance, in agreement with [8] and
[52], who explained that by the fact that elastic net
and SCAD penalties can better deal with correlated
features, which are typically observed in gene expres-
sion data. In our comparison HHSVM, together with
average pathway expression, revealed the highest pre-
diction performance.
It appears in our comparison that incorporation of
biological network knowledge into gene selectionmethods does not necessarily help to improve the pre-
diction accuracy of prognostic biomarkers. Integrating
additional experimental data, such as microRNA mea-
surements, SNP or CNV data in addition to protein-pro-
tein interaction information might offer an alternative
route to enhance prediction performance as well as sta-
bility and interpretability of biomarker signatures in the
future.
To our knowledge this paper is one of the most detailed
and largest comparisons, which has been conducted so far
to assess the performance of network-based gene selection
methods in a multi-dimensional way. Whereas most pre-
vious approaches concentrated only on one aspect of
gene selection methods, namely prediction perform-
ance, we have here also looked to stability and inter-
pretability of the tested algorithms. Prognostic and
diagnostic gene signatures are applied in a biomedical
context. Thus, the classical machine learning based
perspective of focusing only on prediction perform-
ance might be too narrow. Indeed we believe that sta-
bility and interpretability of gene signatures will
strongly enhance their acceptance and practical ap-
plicability for personalized medicine. Here we see the
largest potential for methods, which incorporate bio-
logical background knowledge, for example in form of
pathway knowledge, known disease relations or other
approaches. This does not, of course, imply that pre-
diction performance should be sacrificed for reprodu-




Figure 3 Interpretability of signatures (enriched disease genes). For aveExpPath and PAC the enrichment of the particular disease category
within selected pathway genes is shown. A represents data GSE2034 [34]; B represents data GSE11121 [39]; C represents data GSE1456 [35];
D represents data GSE2990 [36]; E represents data GSE4922 [37]; F represents data GSE7390 [38].






Figure 4 Interpretability of signatures (enriched KEGG-pathways). For aveExpPath the adjusted p-value for differential expression from the
SAM-test is shown. For all other methods we tested pathway enrichment within the set of selected genes.
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Figure 5 Interpretability of signatures (enriched drug targets). For aveExpPath and PAC the enrichment of drug targets within selected
pathway genes is shown.
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Additional file 1: Table S1. Known drug targets for breast neoplasms.
Additional file 2: Figure S1. Stability of each gene selection methods.
The y-axis shows the fraction of genes, being selected 1–10, 11–20, 21–
30, 31–40, 41–50, 51–60, 61–70, 71–80, 81–90 and 91–100 times. PAM
(prediction analysis of microarray data), sigGenNB (SAM+Naïve Bayes),
sigGenSVM (SAM+ SVM),SCAD-SVM, HHSVM (Huberized Hinge loss SVM),
RFE (Recursive Feature Elimination), RRFE (Reweighted Recursive Feature
Elimination), graphK (graph diffusion kernels for SVMs), graphKp (p-step
random walk graph kernel for SVMs), networkSVM (Network-based SVM),
PAC (Pathway Activity Classification), aveExp-Path (average pathway
expression), HubClassify (classification by significant hub genes),
pathBoost.
Additional file 3: Figure S2. Median AUC values across all datasets.
Additional file 4: Table S2. Tukey's post-hoc test analysis for AUC
values (5% significance cutoff).
Additional file 5: Table S3. Tukey's post-hoc test analysis for SI values
(5% significance cutoff).
Additional file 6: Figure S3. Number of selected genes per method.
Additional file 7: Figure S4. Fraction of differentially expression genes
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